FDA Approves Pembrolizumab for Hodgkin Lymphoma

March 14, 2017 – The FDA has granted an accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with classical Hodgkin lymphoma (cHL) who are refractory or have relapsed after 3 or more lines of therapy. The approval is based on data from the nonrandomized, open-label KEYNOTE-087 trial, in which, at a median follow-up of 9.4 months, the overall response rate (ORR) with pembrolizumab was 69% (95% CI, 62- … (leggi tutto)